KSPM
Search
- Page Path
- HOME > Search
Original Article
- Demographic and Survivorship Disparities in Non–muscle-invasive Bladder Cancer in the United States
- Munseok Seo, James R. Langabeer II
- J Prev Med Public Health. 2018;51(5):242-247. Published online August 23, 2018
- DOI: https://doi.org/10.3961/jpmph.18.092
- 5,916 View
- 156 Download
- 14 Crossref
-
Abstract
PDF - Objectives
To examine survivorship disparities in demographic factors and risk status for non–muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. Methods: We used the US National Cancer Institute’s Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan-Meier (K-M) and Cox proportional hazard methods for survival analysis. Results: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. Conclusions: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients. -
Summary
Citations
Citations to this article as recorded by
- N6-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges
Congjie Xu, Jiaquan Zhou, Xiaoting Zhang, Xinli Kang, Shuan Liu, Mi Song, Cheng Chang, Youtu Lin, Yang Wang
Cellular & Molecular Biology Letters.2024;[Epub] CrossRef - Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer
Angela Estevez, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Joaquim Bellmunt, Aria F. Olumi, Heidi Rayala, Boris Gershman
Urologic Oncology: Seminars and Original Investigations.2023; 41(5): 255.e15. CrossRef - Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
Kristin Grabe-Heyne, Christof Henne, Paramananthan Mariappan, Götz Geiges, Johannes Pöhlmann, Richard F. Pollock
Frontiers in Oncology.2023;[Epub] CrossRef - Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
Mihaela Georgiana Musat, Christina Soeun Kwon, Elizabeth Masters, Slaven Sikirica, Debduth B Pijush, Anna Forsythe
ClinicoEconomics and Outcomes Research.2022; Volume 14: 35. CrossRef - Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013
Kelly K. Bree, Yong Shan, Patrick J. Hensley, Niyati Lobo, Chengrui Hu, Douglas S. Tyler, Karim Chamie, Ashish M. Kamat, Stephen B. Williams
JAMA Network Open.2022; 5(3): e223050. CrossRef - Gender Disparities in Bladder Cancer-Specific Survival in High Poverty Areas Utilizing Ohio Cancer Incidence Surveillance System (OCISS)
Laura Bukavina, Megan Prunty, Kirtishri Mishra, Helen Sun, David Sheyn, Britt Conroy, Amr Mahran, Gregory MacLennan, Fredrick Schumacher, Lee Ponsky, Sarah Markt
Urology.2021; 151: 163. CrossRef - Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy
Shang Huang, Hanzhong Chen, Teng Li, Xiaoyong Pu, Jiumin Liu, Xuecheng Bi
BMC Geriatrics.2021;[Epub] CrossRef - Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions
Kuan-Wei Shih, Wei-Chieh Chen, Ching-Hsin Chang, Ting-En Tai, Jeng-Cheng Wu, Andy C. Huang, Ming-Che Liu
Aging and disease.2021; 12(3): 868. CrossRef - The impact of the social construct of race on outcomes among bacille Calmette‐Guérin‐treated patients with high‐risk non‐muscle–invasive bladder cancer in an equal‐access setting
Corinne Lawler, Lin Gu, Lauren E. Howard, Brandee Branche, Emily Wiggins, Aditya Srinivasan, Meagan L. Foster, Zachary Klaassen, Amanda M. De Hoedt, Jeffrey R. Gingrich, Dan Theodorescu, Stephen J. Freedland, Stephen B. Williams
Cancer.2021; 127(21): 3998. CrossRef - Effect of Intravesical Chemotherapy on the Survival of Patients with Non-Muscle-Invasive Bladder Cancer Undergoing Transurethral Resection: A Retrospective Cohort Study Among Older Adults
Ashis K. Das, Devi K. Mishra, Saji S. Gopalan
The Open Urology & Nephrology Journal.2021; 14(1): 20. CrossRef - Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study
Liangjun Tao, Xinyuan Pan, Lixiang Zhang, Jiawei Wang, Zican Zhang, Li Zhang, Chaozhao Liang
Frontiers in Oncology.2020;[Epub] CrossRef - Back pain following instillations of BCG for superficial bladder cancer is not a reactive complication: review of 30 Mycobacterium bovis BCG vertebral osteomyelitis cases
Simon Cadiou, Omar Al Tabaa, Chi-Duc Nguyen, Marine Faccin, Raphaël Guillin, Matthieu Revest, Pascal Guggenbuhl, Eric Houvenagel, Edouard Pertuiset, Guillaume Coiffier
Clinical Rheumatology.2019; 38(6): 1773. CrossRef - Does Health Insurance Modify the Association Between Race and Cancer-Specific Survival in Patients with Urinary Bladder Malignancy in the U.S.?
Juliana Morales, Aaron Malles, Marrell Kimble, Pura Rodriguez de la Vega, Grettel Castro, Alan M. Nieder, Noël C. Barengo
International Journal of Environmental Research and Public Health.2019; 16(18): 3393. CrossRef - Чи може бути гормонотерапія елементом комбінованого радикального лікування хворих на низькодиференційований рак сечового міхура?
P. G. Yakovlev
Шпитальна хірургія. Журнал імені Л. Я. Ковальчука.2019; (3): 75. CrossRef
First
Prev
